Text Size

Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by University of Zurich.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00526695
First received: August 27, 2007
Last updated: July 17, 2008
Last verified: July 2008
History of Changes
  Purpose

Sevoflurane preconditioning and cardiovascular protection against ischemia/reperfusion injury.

Study hypothesis: The volatile anesthetic sevoflurane at subanesthetic concentrations achieves endothelial protection against ischemia/reperfusion injury and reduces inflammatory markers in the circulation


Condition Intervention Phase
Ischemia/Reperfusion Injury
 Drug: Sevoflurane (Preconditioning)
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion, Leukocyte/Thrombocyte Activation, and Endothelial Function After Tourniquet-Induced Ischemia/Reperfusion Injury in the Forearm of Volunteers

Resource links provided by NLM:

Drug Information available for: Sevoflurane
U.S. FDA Resources

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • marker expression on blood cells [ Time Frame: December 2008 ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: January 2005
Estimated Study Completion Date: December 2008
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Sevoflurane (Preconditioning)
    Inhalation of sub-anesthetic doses of sevoflurane
Detailed Description:

Healthy volunteers are included in the study to investigate endothelial function and platelet activation after preconditioning by sevoflurane in subanesthetic concentrations.

Forearm perfusion, endothelial function and leukocyte/thrombocyte activation after tourniquet-induced ischemia/reperfusion injury of the forearm are measured using healthy volunteers in a cross-over design.

  Eligibility

Ages Eligible for Study:   25 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria: male

  • Non-smoker
  • No asthma
  • NPO
  • Volunteer

Exclusion criteria:

  • Female
  • Chronic medication
  • Asthma
  • Smoking
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00526695

Contacts
Contact: 01 Studienregister MasterAdmins +41 (0)44 255 11 11

Locations
Switzerland
University Hospital of Zurich Recruiting
Zurich, Switzerland
Contact: Michael Zaugg, MD         michael.zaugg@usz.ch    
Principal Investigator: Michael Zaugg, MD            
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Michael Zaugg, PD Dr. med. UniversitaetsSpital Zuerich
Principal Investigator: Michael Zaugg, PD Dr. med. University of Zurich
  More Information

No publications provided by University of Zurich

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Michael Zaugg, Anesthesiology, Univ. Hospital Zurich
ClinicalTrials.gov Identifier: NCT00526695     History of Changes
Other Study ID Numbers: 17-2005
Study First Received: August 27, 2007
Last Updated: July 17, 2008
Health Authority: Switzerland: Swissmedic

Keywords provided by University of Zurich:
Ischemia/Reperfusion
Organ Protection
Anesthetics

Additional relevant MeSH terms:
Ischemia
Reperfusion Injury
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Postoperative Complications
Anesthetics
Sevoflurane
Central Nervous System Depressants
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Platelet Aggregation Inhibitors
Hematologic Agents
Anesthetics, Inhalation
Anesthetics, General

ClinicalTrials.gov processed this record on May 19, 2013